Unravelling the mechanisms of scar formation in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and possibly fatal lung disease which involves irreversible scarring of the lung. Current treatments for IPF have limited success. Previous research has suggested that IPF arises when there is an unusually low amount of an enzyme called "COX-2" in the lungs. COX-2 is involved in protecting the lungs from scarring and therefore, a reduced amount of the enzyme leaves the lung more susceptible to it.

Scientists don't yet understand why some people do not produce enough COX-2. Dr Pang and her team intend to study this process in order to find out what the molecular mechanisms are that lead to this lack of COX-2. If they can find out why the deficiency occurs, they will be better equipped to begin formulating new ways to boost levels of the enzyme and hopefully prevent or treat IPF.

Grant: Project Grant
Duration: 24 months
Amount awarded: £107,741
Relevant disease area(s): idiopathic pulmonary fibrosis
Relevant age group(s): all